Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. French.

PMID:
30343945
2.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. French.

PMID:
30337201
3.

[Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].

Simonneau Y, Ruppert AM, Chaabane N, Lavolé A, Wislez M.

Bull Cancer. 2018 Oct;105(10):854-856. doi: 10.1016/j.bulcan.2018.07.016. Epub 2018 Sep 24. French. No abstract available.

PMID:
30262415
4.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.

Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. French.

PMID:
30243521
5.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, Tulasne D, Cortot AB.

Rev Mal Respir. 2018 Oct;35(8):796-812. doi: 10.1016/j.rmr.2018.01.011. Epub 2018 Aug 31. Review. French.

PMID:
30174236
6.

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.

Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.

J Thorac Oncol. 2018 Dec;13(12):1962-1967. doi: 10.1016/j.jtho.2018.08.008. Epub 2018 Aug 24.

PMID:
30149144
7.

Lung cancer and interstitial lung disease: a literature review.

Naccache JM, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J.

J Thorac Dis. 2018 Jun;10(6):3829-3844. doi: 10.21037/jtd.2018.05.75. Review.

8.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:
29764856
9.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

10.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

PMID:
29545318
11.

Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer.

Ruppert AM, Mignard X, Wislez M.

Ann Transl Med. 2017 Dec;5(23):460. doi: 10.21037/atm.2017.09.05. No abstract available.

12.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

13.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
14.

[Lung cancer in HIV-infected patients].

Domblides C, Canellas A, Wislez M, Fallet V, Antoine M, Crequit P, Cadranel J, Lavolé A.

Bull Cancer. 2018 Jan;105(1):111-119. doi: 10.1016/j.bulcan.2017.11.002. Epub 2017 Dec 22. Review. French.

PMID:
29269175
15.

Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer.

Giroux Leprieur E, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B.

Oncotarget. 2017 Oct 10;8(61):103744-103757. doi: 10.18632/oncotarget.21781. eCollection 2017 Nov 28.

16.

Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.

Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M.

AIDS. 2018 Feb 20;32(4):461-468. doi: 10.1097/QAD.0000000000001713.

PMID:
29194117
17.

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma.

Duruisseaux M, Rabbe N, Antoine M, Vieira T, Poulot V, Cadranel J, Wislez M.

ERJ Open Res. 2017 Mar 31;3(1). pii: 00047-2016. doi: 10.1183/23120541.00047-2016. eCollection 2017 Jan.

18.

[Toward new modalities of surveillance in lung cancer patients?]

Domblides C, Chaabane N, Wislez M.

Bull Cancer. 2017 Sep;104(9):703-704. doi: 10.1016/j.bulcan.2017.07.004. Epub 2017 Aug 8. French. No abstract available.

PMID:
28801133
19.

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.

Sesé L, Nunes H, Cottin V, Sanyal S, Didier M, Carton Z, Israel-Biet D, Crestani B, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Guillot-Dudoret S, Nardi A, Dury S, Giraud V, Gondouin A, Juvin K, Borie R, Wislez M, Valeyre D, Annesi-Maesano I.

Thorax. 2018 Feb;73(2):145-150. doi: 10.1136/thoraxjnl-2017-209967. Epub 2017 Aug 10.

PMID:
28798214
20.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

PMID:
28798090
21.

Lymphoproliferative Disorders of the Lung.

Borie R, Wislez M, Antoine M, Cadranel J.

Respiration. 2017;94(2):157-175. doi: 10.1159/000477740. Epub 2017 Jun 14. Review.

22.

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.

Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, Poulot V, Duchêne B, Van Seuningen I, Cadranel J, Wislez M.

Lung Cancer. 2017 Jul;109:92-100. doi: 10.1016/j.lungcan.2017.05.007. Epub 2017 May 10.

PMID:
28577958
23.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

24.

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.

Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J.

Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10.

25.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.

Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.

Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

PMID:
28419182
26.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M.

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

27.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

28.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. Review.

PMID:
28376232
29.

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

Domblides C, Antoine M, Lavole A, Cadranel J, Wislez M.

Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22. French.

PMID:
28237354
30.

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.

Giroux-Leprieur E, Fallet V, Cadranel J, Wislez M.

Lung Cancer (Auckl). 2016 Jun 17;7:83-90. doi: 10.2147/LCTT.S99303. eCollection 2016. Review.

31.

Diagnostic and therapeutic strategy in lung cancer

Rozensztajn N, Créquit P, Wislez M, Cadranel J.

Rev Prat. 2017 Jan;67(1):40-46. French.

PMID:
30512432
32.

[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].

Vignot S, André T, Gonçalves A, Guièze R, Magné N, Orbach D, Penel N, Thariat J, Wislez M, Bay JO.

Bull Cancer. 2017 Jan;104(1):6-19. doi: 10.1016/j.bulcan.2016.11.009. Epub 2016 Dec 19. Review. French.

PMID:
28007296
33.

[Perioperative therapies in surgical non N2 non-small cell lung cancer].

Ruppert AM, Lavolé A, Assouad J, Cadranel J, Wislez M.

Bull Cancer. 2017 Jan;104(1):79-85. doi: 10.1016/j.bulcan.2016.10.017. Epub 2016 Nov 29. Review. French.

PMID:
27912893
34.

[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].

Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M.

Bull Cancer. 2016 Oct;103(10):815-821. doi: 10.1016/j.bulcan.2016.06.007. Epub 2016 Sep 15. French.

PMID:
27641462
35.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
36.

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.

Duruisseaux M, McLeer-Florin A, Antoine M, Alavizadeh S, Poulot V, Lacave R, Rabbe N, Cadranel J, Wislez M.

Cancer Med. 2016 Dec;5(12):3579-3585. doi: 10.1002/cam4.838. Epub 2016 Oct 21.

37.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.

Borie R, Wislez M, Antoine M, Copie-Bergman C, Thieblemont C, Cadranel J.

Eur Respir J. 2016 Oct;48(4):1252. doi: 10.1183/13993003.01143-2016. No abstract available.

38.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

Monnet I, Audigier-Valette C, Girard N, Vergnenègre A, Molinier O, Souquet PJ, Blanchon F, Bonnetain F, Taguieva-Pioger N, Lamour C, Wislez M.

Lung Cancer. 2016 Aug;98:84-90. doi: 10.1016/j.lungcan.2016.05.016. Epub 2016 May 26.

PMID:
27393512
39.

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.

Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M.

Lung Cancer. 2016 Aug;98:51-58. doi: 10.1016/j.lungcan.2016.05.013. Epub 2016 May 21.

40.

Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility.

Denny SK, Yang D, Chuang CH, Brady JJ, Lim JS, Grüner BM, Chiou SH, Schep AN, Baral J, Hamard C, Antoine M, Wislez M, Kong CS, Connolly AJ, Park KS, Sage J, Greenleaf WJ, Winslow MM.

Cell. 2016 Jul 14;166(2):328-342. doi: 10.1016/j.cell.2016.05.052. Epub 2016 Jun 30.

41.

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur Respir J. 2016 Sep;48(3):861-72. doi: 10.1183/13993003.01695-2015. Epub 2016 Jun 23.

42.

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?

Cadranel J, Wislez M, Langlais A, Morin F, Zalcman G.

Eur Respir J. 2016 Jun;47(6):1890-1. doi: 10.1183/13993003.01936-2015. No abstract available.

43.

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.

Créquit P, Ruppert AM, Rozensztajn N, Gounant V, Vieira T, Poulot V, Antoine M, Chouaid C, Wislez M, Cadranel J, Lavole A.

Lung Cancer. 2016 Jun;96:74-7. doi: 10.1016/j.lungcan.2015.11.021. Epub 2015 Nov 28.

PMID:
27133754
44.

[MET exon 14 mutation, new target in lung sarcomatoid carcinoma].

Domblides C, Cortot A, Wislez M.

Bull Cancer. 2015 Dec;102(12):966. French. No abstract available.

PMID:
27064153
45.

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

Wislez M, Domblides C, Cortot A, Lemoine A.

Ann Transl Med. 2016 Mar;4(5):96. doi: 10.21037/atm.2016.01.12. No abstract available.

46.

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

Giroux Leprieur E, Wislez M.

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25. French. No abstract available.

PMID:
26822904
47.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.

Borie R, Wislez M, Antoine M, Copie-Bergman C, Thieblemont C, Cadranel J.

Eur Respir J. 2016 Apr;47(4):1244-60. doi: 10.1183/13993003.01701-2015. Epub 2016 Jan 21. Review.

48.

[2015 through the eyes of the Bulletin of Cancer editorial board].

Magné N, Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Penel N, Rancoule C, Vignot S.

Bull Cancer. 2016 Jan;103(1):3-17. doi: 10.1016/j.bulcan.2015.11.006. Epub 2016 Jan 15. French.

PMID:
26782079
49.

[Pulmonary sarcomatoid carcinoma].

Antoine M, Vieira T, Fallet V, Hamard C, Duruisseaux M, Cadranel J, Wislez M.

Ann Pathol. 2016 Jan;36(1):44-54. doi: 10.1016/j.annpat.2015.11.007. Epub 2016 Jan 8. Review. French.

PMID:
26778815
50.

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].

Hamard C, Ruppert AM, Lavole A, Rozensztajn N, Antoine M, Cadranel J, Wislez M.

Ann Pathol. 2016 Jan;36(1):63-72. doi: 10.1016/j.annpat.2015.11.002. Epub 2016 Jan 6. Review. French.

PMID:
26775573

Supplemental Content

Loading ...
Support Center